• Youn-Jee Chung, Boah Chae, Se-Hyun Kwak, Jae-Yen Song, Ah-Won Lee, Hyun-Hee Jo, Young-Ok Lew, Jang-Heub Kim, and Mee-Ran Kim.
• 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
• Int J Med Sci. 2014 Jan 1; 11 (3): 276-81.

AbstractUterine myomas are the most common gynecologic tumor in women of reproductive age. Treatment options of uterine myomas consist of surgical, medical and interventional therapy such as uterine artery embolization or myolysis. Given that it is the most common type of tumor in women of reproductive age, the treatment of uterine myomas must prioritize uterine conservation. There are several drugs for medical treatment of uterine myoma such as gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM) and antiprogesterone. The objective of this study was to compare the effect of GnRH agonist, SERM, and antiprogesterone in the treatment of uterine myomas in vitro. The effect of drugs was evaluated through the cell viability assay in cultured leiomyoma cells, western blot analysis of proliferating cell nuclear antigen (PCNA), and BCL-2 protein expression. As a result, mifepristone single-treated group represents the most significant reduction in myoma cell viability and proliferation. When pretreated with leuprolide acetate, raloxifene shows more significant reduction in myoma cell viability and proliferation than mifepristone. This study suggests one of the possible mechanisms how medications act on uterine myoma, especially at the molecular level.

37 keywords...

hide…